Pramipexole

Uses your system voice; voice and rate in settings.

Snapshot

≈ 7 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth.

Pramipexole is a dopamine agonist of the non-ergoline class. Pramipexole was approved for medical use in the United States in 1997 and was first manufactured by Pharmacia and Upjohn. It is available as a generic medication.

In 2023, it was the 201st most commonly prescribed medication in the United States, with more than 2 million prescriptions.

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth.

Pramipexole is a dopamine agonist of the non-ergoline class. Pramipexole was approved for medical use in the United States in 1997 and was first manufactured by Pharmacia and Upjohn. It is available as a generic medication.

In 2023, it was the 201st most commonly prescribed medication in the United States, with more than 2 million prescriptions.

Medical uses

Pramipexole is used in the treatment of Parkinson's disease and restless legs syndrome. Safety in pregnancy and breastfeeding is unknown. A 2008 meta-analysis found that pramipexole was more effective than ropinirole in the treatment of restless legs syndrome.

It is occasionally prescribed off-label for depression. Its effectiveness as an antidepressant may be a product of its strong partial agonistic activity on and preferential occupation of dopamine D 3 receptors at low doses (see table below); as well, the drug has been shown to desensitize the inhibitory D 2 autoreceptors but not the postsynaptic D 2 receptors, leading to an increase in dopamine and serotonin levels in the prefrontal cortex.

Chronic administration of pramipexole may also result in desensitization of D 3 autoreceptors, leading to reduced dopamine transporter function. Trials have shown mixed results for depression. Pramipexole has also been used as a treatment for REM sleep behavior disorder, but it is not licensed for use in this disorder.

Observational studies suggest it may reduce the frequency and intensity of REM sleep behavior disorder symptoms, but randomized controlled trials have not been performed, so the evidence for its role in this disorder is weak.

Side effects

Common side effects of pramipexole include: Headache Peripheral edema Hyperalgesia (body aches and pains) Nausea and vomiting Sedation and somnolence Decreased appetite and subsequent weight loss Orthostatic hypotension (resulting in dizziness, lightheadedness, and possibly fainting, especially when standing up) Insomnia Hallucinations (seeing, hearing, smelling, tasting or feeling things that are not there), amnesia and confusion Twitching, twisting, or other unusual body movements Unusual tiredness or weakness Pramipexole (and related D 3 -preferring dopamine agonist medications such as ropinirole) can induce "impulsive–compulsive spectrum disorders" such as compulsive gambling, punding, hypersexuality, and overeating, even in people without any prior history of these behaviors. There have also been reported detrimental side effects related to impulse-control disorders resulting from off-label use of pramipexole or other dopamine agonists in treating clinical depression.

The incidence and severity of impulse-control disorders for those taking the drug for depression are not fully understood because the drug has not been approved for the treatment of depression and the first major studies of its efficacy in treating anhedonic depression were conducted in 2022. There have been anecdotal reports of abrupt and severe personality changes related to impulsivity and loss of self-control in a minority of patients regardless of the condition being treated, although the incidence of these side effects is not yet fully known.

Augmentation: Especially when used to treat restless legs syndrome, long-term pramipexole treatment may exhibit drug augmentation, which is "an iatrogenic worsening of [restless legs syndrome] symptoms following treatment with dopaminergic agents" and may include an earlier onset of symptoms during the day or a generalized increase in symptoms.

Pharmacology

The activity profile of pramipexole at various sites has been characterized as follows: While pramipexole is used clinically (see below), its D 3 -preferring receptor binding profile has made it a popular tool compound for preclinical research. For example, pramipexole has been used (in combination with D 2 - and or D 3 -preferring antagonists) to discover the role of D 3 receptor function in rodent models and tasks for neuropsychiatric disorders.

Of note, it appears that pramipexole, in addition to having effects on dopamine D 3 receptors, may also affect mitochondrial function via a mechanism that remains less understood. A pharmacological approach to separate dopaminergic from non-dopaminergic (e.g. mitochondrial) effects of pramipexole has been to study the effects of the R-stereoisomer of pramipexole (which has much lower affinity to the dopamine receptors when compared to the S-isomer) side by side with the effects of the S-isomer.

This property can be characterised using dopaminergic activity equivalent (a relative measure comparing doses of different doses of stereoisomers in mg). Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia.

The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia.

When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired.

By acting as an agonist for the D 2 , D 3 , and D 4 dopamine receptors, pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia. Pramipexole can increase growth hormone indirectly through its inhibition of somatostatin.

Pramipexole has also been shown to be protective against dopaminergic-related methamphetamine neurotoxicity. Immediate-release pramipexole displays a T max of approximately 2 hours and 3 hours if taken with a high-fat meal. Extended-release pramipexole displays a T max of ~6 hours and ~8 hours if taken with food.

The AUC of pramipexole remains unaltered regardless of food presence. Steady-state is achieved within 3 days and 5 days for the IR and ER formulations, respectively. Pramipexole is eliminated via the renal organic cation transporter as an unchanged drug showing no signs of any metabolism.

Pramipexole has been shown to inhibit CYP2D6 with a K i of 30μM which is significantly higher than the maximum approved dosage of 4.5mg/day thus any enzyme-mediated drug interactions are not clinically relevant. It comes in strengths of 0.125mg, 0.25mg, 0.5mg, 1mg, and 1.5mg instant release; the extended-release comes in 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, and 4.5mg.

The instant release is meant to be dosed three times daily for Parkinson's and once two hours before bedtime for restless leg syndrome. The extended-release is not approved for restless leg syndrome. It is not metabolized, with >90% of the dose excreted unchanged via SCL22A2/OCT2.

Therefore, inhibitors of the renal organic cation transporter system (e.g., cimetidine ) will increase the area under the curve \infty by 50% and increase the t 1/2 by 40%.

Analogues

Derivatives of pramipexole include CJ-998, CJ-1037, CJ-1638, CJ-1639, D-264, D-440, and D-512. Some analogues of pramipexole include etrabamine and talipexole. Another notable analogue of pramipexole is matsupexole.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377184320 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

26 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.